Interim Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash Flows From Operating Activities:
Net income	$ 26,290,000	$ 32,335,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	14,766,000	14,037,000
Provision for doubtful accounts receivable	1,141,000	1,033,000
Equity in earnings of unconsolidated investments	(6,016,000)	(4,738,000)
Distributions from unconsolidated investments	4,394,000	2,942,000
Gains on sale of restricted marketable securities	(987,000)	(164,000)
Deferred income taxes	(1,519,000)	(328,000)
Stock–based compensation	1,398,000	1,753,000
Changes in operating assets and liabilities:
Restricted cash and cash equivalents	(3,420,000)	(3,438,000)
Accounts receivable	3,076,000	9,448,000
Income tax receivable	3,779,000
Inventories	625,000	214,000
Prepaid expenses and other assets	(1,230,000)	(1,214,000)
Trade accounts payable	(3,556,000)	900,000
Accrued payroll	(14,640,000)	(14,258,000)
Amounts due to third party payors	(125,000)	39,000
Other current liabilities and accrued risk reserves	5,222,000	(13,104,000)
Entrance fee deposits	(986,000)	(449,000)
Other noncurrent liabilities	343,000	42,000
Deferred income	1,930,000	2,108,000
Net cash provided by operating activities	30,485,000	27,158,000
Cash Flows From Investing Activities:
Additions to property and equipment	(6,242,000)	(13,352,000)
Acquisition of non-controlling interest in hospice business	(7,500,000)
Collections of notes receivable, net	20,000	1,139,000
Change in restricted cash and cash equivalents	1,070,000	5,231,000
Purchase of restricted marketable securities	(36,228,000)	(30,023,000)
Sale of restricted marketable securities	33,871,000	23,532,000
Net cash used in investing activities	(15,009,000)	(13,473,000)
Cash Flows From Financing Activities:
Tax (expense) benefit from stock–based compensation	(270,000)	120,000
Dividends paid to preferred stockholders	(4,336,000)	(4,336,000)
Dividends paid to common stockholders	(8,348,000)	(7,668,000)
Issuance of common shares	5,583,000	7,152,000
Change in deposits	96,000	(100,000)
Net cash used in financing activities	(7,275,000)	(4,832,000)
Net Increase in Cash and Cash Equivalents	8,201,000	8,853,000
Cash and Cash Equivalents, Beginning of Period	61,008,000	28,478,000
Cash and Cash Equivalents, End of Period	$ 69,209,000	$ 37,331,000